ERBB2 and cancer: The cancer panel comprised HT29 (colorectal), U87 (brain), SJ-G2 (brain), A2780 (ovary), Du145 (prostate), BE2-C (neuronal), MIA (pancreas), H460 (lung, ER+), A431 (vulva, ER+ (estrogen receptor positive)), and a wide selection of breast cancer cell lines with varying receptor status including MCF-7 (ER + luminal A), T47D (ER/PR+ (progesterone receptor positive)luminal A), ZR-75-1 (ER/PR + luminal A), BT-474 (ER/PR/HER2+ luminal B), SKBR-3 (HER2+), MDA-MB-468, BT20, and MDA-MB-231 (basal, triple negative (TN) for ER, PR, and HER2).